Zacks Research Has Strong Forecast for PBYI FY2026 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Investment analysts at Zacks Research lifted their FY2026 earnings estimates for shares of Puma Biotechnology in a report issued on Thursday, August 27th. Zacks Research analyst Team now expects that the biopharmaceutical company will post earnings per share of $0.37 for the year, up from their prior forecast of $0.31. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q1 2027 earnings at $0.04 EPS, Q2 2027 earnings at $0.07 EPS, Q4 2027 earnings at $0.02 EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.45 EPS.

Other research analysts have also recently issued research reports about the stock. Wall Street Zen raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 15th. TD Cowen boosted their target price on shares of Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a report on Friday, August 7th. Finally, Weiss Ratings raised shares of Puma Biotechnology from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 21st. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.

Puma Biotechnology Stock Performance

NASDAQ PBYI opened at $9.69 on Thursday. Puma Biotechnology has a fifty-two week low of $4.30 and a fifty-two week high of $9.73. The firm has a market capitalization of $500.20 million, a P/E ratio of 18.63 and a beta of 1.24. The stock’s fifty day moving average is $8.46 and its two-hundred day moving average is $7.49.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.04 by $0.15. Puma Biotechnology had a return on equity of 20.76% and a net margin of 11.50%.The firm had revenue of $56.50 million during the quarter, compared to analysts’ expectations of $53.00 million.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, Director Allison Dorval sold 11,610 shares of Puma Biotechnology stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $7.20, for a total transaction of $83,592.00. Following the completion of the sale, the director directly owned 90,780 shares in the company, valued at $653,616. This trade represents a 11.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Douglas M. Hunt sold 8,460 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $69,879.60. Following the completion of the sale, the insider directly owned 196,841 shares in the company, valued at $1,625,906.66. This trade represents a 4.12% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 132,028 shares of company stock worth $1,006,711 in the last 90 days. Insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc purchased a new stake in Puma Biotechnology during the 2nd quarter worth about $35,000. Royal Bank of Canada lifted its position in Puma Biotechnology by 244.5% in the first quarter. Royal Bank of Canada now owns 4,320 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 3,066 shares during the last quarter. California State Teachers Retirement System boosted its stake in Puma Biotechnology by 110.2% in the second quarter. California State Teachers Retirement System now owns 4,898 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,568 shares in the last quarter. Philadelphia Investment Partners LLC acquired a new stake in shares of Puma Biotechnology during the second quarter worth about $65,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,290 shares during the last quarter. 61.29% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Zacks raised its FY2026 EPS forecast to $0.37 from $0.31, while increasing estimates for Q1 2027 to $0.04 from $0.03 and Q2 2027 to $0.07 from $0.06. These upgrades suggest improved near-term earnings expectations for Puma Biotechnology.
• Positive Sentiment: The FY2028 EPS forecast was lifted to $0.45 from $0.42, indicating stronger long-term profitability expectations. Zacks’ revised FY2026 estimate is also above the current-year consensus of $0.31.
• Neutral Sentiment: Despite the revisions, Zacks projects FY2027 EPS of $0.14 and Q4 2027 EPS of $0.02, reflecting modest expected profitability during portions of the forecast period. The overall outlook is therefore mixed rather than uniformly bullish.
• Negative Sentiment: Zacks cut its FY2027 EPS forecast to $0.14 from $0.18 and reduced Q4 2027 EPS to $0.02 from $0.04. These downgrades point to weaker expected earnings growth in 2027.
• Negative Sentiment: Estimates for Q3 2026 were lowered to $0.06 from $0.08, while Q3 2027 expectations fell to $0.02 from $0.05. The reductions could weigh on sentiment because they imply softer earnings in upcoming or intermediate reporting periods.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.